CJC-1295 (no-DAC) + Ipamorelin Blend Stacking and Combinations
Which compounds CJC-1295 (no-DAC) + Ipamorelin Blend is paired with, and the rationale behind each combination.
Stacking
CJC-1295 is frequently combined with other peptides to enhance its effects.
CJC-1295 + BPC-157
Some users combine CJC-1295 with BPC-157 for enhanced recovery and healing, though this combination lacks clinical research.
Peptide Stacking Guide
Peptide stacking combines two or more peptides in coordinated protocols to achieve synergistic effects for muscle growth, fat loss, recovery, and cognitive enhancement. Learn the most effective stacks, dosing strategies, safety protocols, and monitoring guidelines. “Peptidepedia compiles and maintains peptide information from peer-reviewed research , clinical trials , and verified laboratory data .”
Synergy with Growth Hormone-Releasing Hormone
Ipamorelin's effects are potentiated when the hypothalamus releases endogenous growth hormone-releasing hormone (GHRH). The two pathways work synergistically. GHRH primes the pituitary while ipamorelin amplifies the release signal. This is why many protocols combine ipamorelin with synthetic GHRH analogs like CJC-1295 or Mod GRF 1-29 for enhanced effects.
Advanced Protocol
200 mcg, two to three times daily, often combined with a GHRH analog such as CJC-1295, for 8-12 weeks.
Ipamorelin + CJC-1295 (no DAC) / Mod GRF 1-29
This is the most popular combination. The GHRH analog primes the pituitary while ipamorelin amplifies release, creating a synergistic effect that produces greater GH elevation than either peptide alone. Typical dosing involves equal amounts (e.g., 100 mcg of each) administered simultaneously. See the ipamorelin vs GHRP-6 guide for a comparison of the main GHRP options, or the CJC-1295 vs ipamorelin page for stacking context.
References
- Teichman SL, et al. Prolonged Stimulation of Growth Hormone (GH) and Insulin-Like Growth Factor I Secretion by CJC-1295, a Long-Acting Analog of GH-Releasing Hormone, in Healthy Adults. Journal of Clinical Endocrinology & Metabolism. 2006;91(3):799-805. · Hoffmann P, Feige JJ, Alfaidy N · 2006
- Activation of the GH/IGF-1 axis by CJC-1295, a long-acting GHRH analog, results in serum protein profile changes in normal adult subjects. · Sackmann-Sala L, Ding J, Frohman LA et al. · 2009
- Raun K, et al. Ipamorelin, the first selective growth hormone secretagogue. European Journal of Endocrinology. 1998;139(5):552-561. · Raun K, Hansen BS, Johansen NL, Thøgersen H, Madsen K, Ankersen M, Andersen PH · 1998
- Prospective, randomized, controlled, proof-of-concept study of the Ghrelin mimetic ipamorelin for the management of postoperative ileus in bowel resection patients. · Beck DE, Sweeney WB, McCarter MD et al. · 2014
- Ipamorelin | C38H49N9O5 | CID 9831659 - PubChem - NIH
- Jette L, et al. Human Growth Hormone-Releasing Factor (hGRF)1-29-Albumin Bioconjugates Activate the GRF Receptor on the Anterior Pituitary in Rats: Identification of CJC-1295 as a Long-Lasting GRF Analog. Endocrinology. 2005. · Chung S, Son GH, Park SH, Park E, Lee KH, Geum D, Kim K · 2005